UTHR - Company ID 0001082554
The table below shows UNITED THERAPEUTICS Corp's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $781.50M | $799.50M | $798.60M | $794.40M | $748.90M | $714.90M |
| Cost of revenue | $133.40M | $100.90M | $87.60M | $92.50M | $83.10M | $77.80M |
| Gross profit | $648.10M | $698.60M | $711.00M | $701.90M | $665.80M | $637.10M |
| R&D | $138.20M | $127.50M | $134.00M | $149.00M | $103.50M | $139.60M |
UNITED THERAPEUTICS Corp reported annual revenue of $3.18B for fiscal year 2025. That is up 10.6% from $2.88B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.60B (FY 2016) to $3.18B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $184.10M | $182.60M | $212.50M | $170.10M | $219.20M | $177.60M |
| Operating income | $325.80M | $388.50M | $364.50M | $382.80M | $343.10M | $319.90M |
| Income tax | $43.40M | $99.30M | $98.90M | $101.30M | $79.50M | $77.20M |
| Net income | $274.90M | $338.70M | $309.50M | $322.20M | $309.10M | $278.10M |
| EPS (diluted) | $5.82 | $7.16 | $6.41 | $6.63 | $6.39 | $5.85 |